| Name | Title | Contact Details |
|---|
HNI Healthcare designs intelligent processes and technology to empower talented people to transform healthcare.
A patient-centric continuum of care will exist in the Greater Houston area that enhances overall population health, reduces health and wellness costs, connects all healthcare and wellness services providers and clients, facilitates region-wide healthcare and wellness policies and programs, and advances opportunities for long-term research for disease prevention and cures and evidence-based clinical protocols for optimal care.
PRx is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Senomyx is using proprietary taste science technologies to discover, develop, and commercialize novel flavor ingredients. These include modifiers of Sweet and Salt flavors as well as Savory Flavors, Bitter Blockers, and Cooling Agents. The Company is also engaged in an effort to discover and develop natural high-potency sweeteners. Under its direct sales program, Senomyx is beginning to sell certain of its Complimyx brand flavor ingredients, Sweetmyx, Savorymyx, and Bittermyx, to flavor companies for re-sale to their food and beverage company customers. In addition, Senomyx has collaborative agreements with global food, beverage, and ingredient supply companies, some of which are currently marketing products that contain Senomyx's flavor ingredients.
RaNA Therapeutics is pioneering the discovery of a new class of RNA-targeted medicines that selectively activate protein expression within the body`s own cells. By targeting specific genes, RaNA`s novel drugs work epigenetically to precisely upregulate the expression of beneficial proteins in order to treat or prevent disease. The company`s leadership leverages preeminent founders and advisors in the field, and the strength of its fundamental patents, technology, and know-how that underlie the discovery and development of therapeutics that selectively activate RNA. RaNA is applying its proprietary technology to rapidly advance a pipeline of novel drugs for diverse therapeutic areas, with an initial emphasis in the fields of rare genetic disorders, inflammation, oncology, metabolic diseases and neurodegenerative diseases.